Norges Bank purchased a new position in Astrazeneca Plc (NYSE:AZN – Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 1,276,181 shares of the company’s stock, valued at approximately $223,970,000.
Several other large investors have also recently made changes to their positions in the stock. Fort Sheridan Advisors LLC bought a new position in shares of Astrazeneca in the 4th quarter worth $400,000. Basepoint Wealth LLC bought a new position in shares of Astrazeneca in the 4th quarter worth $44,000. SBI Okasan Asset Management Co.Ltd. bought a new position in shares of Astrazeneca in the 4th quarter worth $4,394,000. Northwestern Mutual Wealth Management Co. raised its position in shares of Astrazeneca by 3.4% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 86,207 shares of the company’s stock worth $15,129,000 after acquiring an additional 2,820 shares in the last quarter. Finally, Kingsview Wealth Management LLC raised its position in shares of Astrazeneca by 1.3% in the 4th quarter. Kingsview Wealth Management LLC now owns 12,299 shares of the company’s stock worth $2,158,000 after acquiring an additional 154 shares in the last quarter. 20.35% of the stock is owned by institutional investors.
Astrazeneca Stock Down 1.3%
Shares of AZN stock opened at $177.34 on Wednesday. The stock’s 50-day simple moving average is $191.20 and its 200-day simple moving average is $184.28. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.71 and a current ratio of 0.91. The firm has a market capitalization of $275.04 billion, a PE ratio of 26.63, a P/E/G ratio of 1.43 and a beta of 0.25. Astrazeneca Plc has a fifty-two week low of $137.23 and a fifty-two week high of $212.71.
Analysts Set New Price Targets
Several research firms have recently commented on AZN. Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Astrazeneca in a research report on Thursday, May 21st. Weiss Ratings initiated coverage on Astrazeneca in a research report on Wednesday, March 11th. They set a “buy (b)” rating on the stock. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Astrazeneca in a research report on Monday. Barclays reaffirmed a “buy” rating on shares of Astrazeneca in a research report on Monday. Finally, Wall Street Zen raised Astrazeneca from a “hold” rating to a “buy” rating in a research report on Saturday, May 2nd. Twelve investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $205.33.
Get Our Latest Stock Analysis on AZN
Astrazeneca Company Profile
AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.
The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.
Further Reading
- Five stocks we like better than Astrazeneca
- Marvell Stock Soars on NVIDIA’s Trillion-Dollar Nod
- FirstCash Turns Pawn Into a Growth Machine
- HubSpot Just Crushed the Bear Case—Is a Bigger Rally Ahead?
- Aggressive Insider Buying Signals Opportunity in 3 Risky Stocks
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astrazeneca Plc (NYSE:AZN – Free Report).
Receive News & Ratings for Astrazeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca and related companies with MarketBeat.com's FREE daily email newsletter.
